Literature DB >> 68972

Immune suppression with supraoptimal doses of antigen in contact sensitivity. I. Demonstration of suppressor cells and their sensitivity to cyclophosphamide.

M S Sy, S D Miller, H N Claman.   

Abstract

Immunologic suppression was induced in a mouse model of contact sensitization to DNFB by using supraoptimal doses of antigen. In these studies, in vivo measurement of ear swelling as an indication of immunologic responsiveness correlated well with measurement of in vitro antigen-induced cell proliferation. This unresponsiveness was specific, since supraoptimal doses of DNFB did not interfere with the development of contact sensitivity to another contactant, oxazolone. The decrease in responsiveness is a form of active suppression, as lymphoid cells from supraoptimally sensitized donors transferred suppression to normal recipients. Furthermore, pretreatment with cyclophosphamide (Cy) reversed the suppression seen in supraoptimally sensitized animals but had no effect on the optimal sensitization regimen. These results indicate that supraoptimal doses of contactants can activate suppressor cells and that precursors of these cells are sensitive to Cy. Such suppressors regenerate within 7 to 14 days after Cy treatment. The ability of Cy pretreatment to affect supraoptimal sensitization without affecting optimal sensitization confirms other reports indicating that the observed results of Cy treatment depend critically upon the dose of antigen used.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 68972

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis.

Authors:  E K Godeny; C J Gauntt
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

2.  Antigen-specific suppressor T cells prevent cardiac injury in Balb/c mice infected with a nonmyocarditic variant of coxsackievirus group B, type 3.

Authors:  M Estrin; C Smith; S Huber
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

3.  Suppression of lymphoproliferation by hapten-specific suppressor T lymphocytes from mice exposed to ultraviolet radiation.

Authors:  S E Ullrich
Journal:  Immunology       Date:  1985-02       Impact factor: 7.397

4.  Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.

Authors:  P M Comoglio; M Prat; S Bretti
Journal:  Immunology       Date:  1985-02       Impact factor: 7.397

5.  Regulation of cellular and humoral immune responses to collagen type I or collagen type II.

Authors:  L Butler; B Simmons; J Zimmerman; P Deriso; K Phadke; J Hom
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

6.  A suppressor B lymphocyte inhibiting IL-2 consumption in spleen cell cultures from Mycobacterium bovis BCG-infected mice.

Authors:  R Turcotte
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

7.  Reversal of suppressed cell-mediated immune reaction by pyrimethamine.

Authors:  J X Zhang; X Z Zhao
Journal:  Acta Acad Med Wuhan       Date:  1985

8.  Contact sensitivity and the DNA response in mice to high and low doses of oxazolone: low dose unresponsiveness following painting and feeding and its prevention by pretreatment with cyclophosphamide.

Authors:  G L Asherson; M A Perera; W R Thomas
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

9.  Differential inhibition of contact sensitivity by suppressor T cells and suppressor factor induced by combined treatment with dinitrobenzenesulphonate and dinitrofluorobenzene.

Authors:  C Zimber; S Ben-Efraim; D W Weiss
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

10.  Enhancement of sheep erythrocyte (SRBC)-induced pleurisy in non-sensitized mice by cyclophosphamide: demonstration of natural cell-mediated immune reactivity to SRBC.

Authors:  S Yamamoto; Y Higuchi; H Teshima
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.